{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:28:41Z","timestamp":1769239721929,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:00:00Z","timestamp":1386892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40273-013-0122-x","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T13:18:25Z","timestamp":1386854305000},"page":"159-172","source":"Crossref","is-referenced-by-count":18,"title":["The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas\u00a0aeruginosa in Patients with Cystic Fibrosis"],"prefix":"10.1007","volume":"32","author":[{"given":"Paul","family":"Tappenden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Harnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Uttley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Mildred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Walshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"122_CR1","unstructured":"Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2010. 2011; p. 1\u201367."},{"issue":"7632","key":"122_CR2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/bmj.39391.713229.AD","volume":"335","author":"JC Davies","year":"2007","unstructured":"Davies JC, Alton EW, Bush A. Clinical review: cystic fibrosis. BMJ. 2007;335(7632):1255\u20139.","journal-title":"BMJ"},{"issue":"6","key":"122_CR3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jpepsy\/25.6.403","volume":"25","author":"AL Quittner","year":"2000","unstructured":"Quittner AL, Sweeney S, Watrous M, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol. 2000;25(6):403\u201314.","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"122_CR4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","volume":"10","author":"MW Konstan","year":"2011","unstructured":"Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011;10(1):54\u201361.","journal-title":"J Cyst Fibros"},{"key":"122_CR5","doi-asserted-by":"crossref","unstructured":"Schuster A, Haliburn C, D\u00f6ring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2012;68(4):344\u201350.","DOI":"10.1136\/thoraxjnl-2012-202059"},{"key":"122_CR6","unstructured":"Tappenden P, Harnan S, Uttley L, et al. Cystic fibrosis (pseudomonas lung infection)\u2014colistimethate sodium and tobramycin: assessment report to the National Institute for Health and Clinical Excellence. 2012. Available from http:\/\/www.nice.org.uk\/ . Accessed: 21 Feb 2013."},{"key":"122_CR7","unstructured":"European Medicines Agency. Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. EMA Research Guideline 2009. Available from http:\/\/www.ema.europa.eu\/docs\/ . Accessed 01 Dec 2012."},{"key":"122_CR8","unstructured":"National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. NICE, London 2008."},{"key":"122_CR9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1183\/09031936.00099506","volume":"29","author":"JA Dodge","year":"2007","unstructured":"Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947\u20132003. Eur Respir J. 2007;29:522\u20136.","journal-title":"Eur Respir J"},{"key":"122_CR10","unstructured":"Forest Laboratories UK Ltd. A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium and nebulised TNSFI (tobramycin nebuliser solution for inhalation, TOBI\u00ae) in cystic fibrosis patients with Pseudomonas aeruginosa lung infection - Clinical Study Report. 2009; p. 1\u20138411."},{"key":"122_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/mpd.2003.51","volume":"142","author":"MS Yi","year":"2003","unstructured":"Yi MS, Britto MT, Wilmott RW, et al. Health values of adolescents with cystic fibrosis. J Paediatr. 2003;142:133\u201340.","journal-title":"J Paediatr"},{"key":"122_CR12","unstructured":"Bradley J, Blume S, Stafford M, et al. Quality of life and health utility in patients with cystic fibrosis. European Respiratory Society Conference; 2010."},{"key":"122_CR13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7525-3-56","volume":"3","author":"E Stahl","year":"2005","unstructured":"Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcome. 2005;3:56.","journal-title":"Health Qual Life Outcome"},{"issue":"3","key":"122_CR14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/thorax.56.3.218","volume":"56","author":"AC Anyanwu","year":"2001","unstructured":"Anyanwu AC, McGuire A, Rogers CA, et al. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax. 2001;56(3):218\u201322.","journal-title":"Thorax"},{"key":"122_CR15","unstructured":"Association of the Royal Pharmaceutical Society of Great Britain. British National Formulary Number 62. 2011."},{"key":"122_CR16","unstructured":"Forest Laboratories UK Ltd. Colobreathe patient access scheme submission to the National Institute for Health and Clinical Excellence. 2012."},{"key":"122_CR17","unstructured":"Patient Access Schemes Liaison Unit, National Institute for Health and Clinical Excellence. Process for advising on the feasibility of implementing a patient access scheme - interim. 2009. Available from: http:\/\/www.nice.org.uk\/media\/FCC\/CC\/PASLUProcessGuide.pdf . Accessed 30 Jan 2013."},{"key":"122_CR18","unstructured":"Department of Health. NHS reference costs 2010\u20132011. 2012. London, Department of Health."},{"key":"122_CR19","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006."},{"key":"122_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1569-1993(03)00064-X","volume":"2","author":"R Iles","year":"2003","unstructured":"Iles R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic evaluation of tobramycin nebuliser solution in cystic fibrosis. J Cyst Fibros. 2003;2:120\u20138.","journal-title":"J Cyst Fibros"},{"key":"122_CR21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1183\/09031936.97.10040896","volume":"10","author":"JM Wolter","year":"1997","unstructured":"Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J. 1997;10:896\u2013900.","journal-title":"Eur Respir J"},{"key":"122_CR22","doi-asserted-by":"crossref","unstructured":"Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros. 2005;4:239\u201347.","DOI":"10.1016\/j.jcf.2005.08.003"},{"key":"122_CR23","unstructured":"Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making. University of Sheffield, Decision Support Unit. p. 1\u201324; 2011."},{"key":"122_CR24","unstructured":"Novartis Pharmaceuticals. Colistimethate sodium powder (Colobreathe\u00ae) and tobramycin powder for inhalation (TOBI Podhaler\u00ae) for the treatment of pseudomonas lung infection in cystic fibrosis - Novartis submission to NICE. 2011."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0122-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-013-0122-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0122-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:50:38Z","timestamp":1716292238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-013-0122-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,13]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1007\/s40273-013-0122-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,13]]}}}